| abstract |
The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralising activity for TGF beta 1 and are useful in treating conditions associated with excess TGF รข1 activity, such as fibrosis, immune responses and tumour progression. |